EU health council's drug legislation proposal not in interest of patients

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1415, 2003-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The New EU Legislation on Pharmacovigilance and Changing Models for Drug Development

By Callréus Torbjörn  

Drug Safety, Vol. 34, Iss. 6, 2011-06 ,pp. : 529-530

Adis International

Access to resources Recommend Favorite

Council of the EU moves to strengthen pharmacovigilance

By  

Reactions Weekly, Vol. 1, Iss. 1331, 2010-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Equity, Access and Economic Evaluation in Rare Diseases: The Impact of Orphan Drug Legislation on Health Policy and Patient Care

By Bosanquet N.  

Pharmaceutical Development and Regulation, Vol. 1, Iss. 3, 2003-01 ,pp. : 151-157

Adis International

Access to resources Recommend Favorite

Health policy on drug trials in paediatric patients

By  

Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

EU orphan drug designations

By  

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite